Circumcision Status and Incident HSV-2 Infection, Genital Ulcer Disease, and HIV Infection
journal contributionposted on 05.12.2013 by Supriya D. Mehta, Stephen Moses, Corette B. Parker, Kawango Agot, Ian Maclean, Robert C. Bailey
Any type of content formally published in an academic journal, usually following a peer-review process.
Objective: We assessed the protective effect of medical male circumcision (MMC) against HIV, HSV-2, and GUD incidence. Design: 2784 men aged 18–24 years living in Kisumu, Kenya were randomly assigned to circumcision (n=1391) or delayed circumcision (n=1393), and assessed by HIV and HSV-2 testing and medical examinations during follow-ups at 1, 3, 6, 12, 18, and 24 months. Methods: Cox regression estimated the risk ratio (RR) of each outcome (incident HIV, GUD, HSV-2) for circumcision status and multivariable models estimated HIV risk associated with HSV-2, GUD and circumcision status as time-varying covariates. Results: HIV incidence was 1.42 per 100 person-years. Circumcision was 62% protective against HIV [RR=0.38; 95% CI: 0.22 - 0.67], and did not change when controlling for HSV-2 and GUD [RR=0.39; 95% CI: 0.23 - 0.69]. GUD incidence was halved among circumcised men [RR=0.52, 95% CI: 0.37 - 0.73]. HSV-2 incidence did not differ by circumcision status [RR=0.94; 95% CI: 0.70 - 1.25]. In the multivariable model, HIV seroconversions were tripled [RR=3.44; 95% CI: 1.52 - 7.80] among men with incident HSV-2 and 7 times greater [RR=6.98; 95% CI: 3.50 - 13.9] for men with GUD. Conclusion: Contrary to findings from the South African and Ugandan trials, the protective effect of MMC against HIV was independent of GUD and HSV-2 and MMC had no effect on HSV-2 incidence. Determining the causes of GUD is necessary to reduce associated HIV risk, and to understand how circumcision confers protection against GUD and HIV.